Dorsal Dupuytren’s disease: a systematic review of published cases and treatment options

Carloni, Raphaël; Gandolfi, Silvia; Elbaz, Bénédicte; Bonmarchand, Albane; Beccari, R.; Auquit-Auckbur, I.

doi:10.1177/1753193419852171

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study findings are almost in line with these research works. However, the cause of the minor differences between the present study and these pieces of research can be justified based on the number of articles reviewed in the present study which is higher (85 articles in the present study vs. 17 articles in the study of Carloni et al [ 76 ] and 23 articles in the study of Lanting et al [ 75 ]). Moreover, the present study examined patients with different races and geographical locations worldwide.…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background The Dupuytren disease is a benign fibroproliferative disorder that leads to the formation of the collagen knots and fibres in the palmar fascia. The previous studies reveal different levels of Dupuytren’s prevalence worldwide; hence, this study uses meta-analysis to approximate the prevalence of Dupuytren globally. Methods In this study, systematic review and meta-analysis have been conducted on the previous studies focused on the prevalence of the Dupuytren disease. The search keywords were Prevalence, Prevalent, Epidemiology, Dupuytren Contracture, Dupuytren and Incidence. Subsequently, SID, MagIran, ScienceDirect, Embase, Scopus, PubMed and Web of Science databases and Google Scholar search engine were searched without a lower time limit and until June 2020. In order to analyse reliable studies, the stochastic effects model was used and the I2 index was applied to test the heterogeneity of the selected studies. Data analysis was performed within the Comprehensive Meta-Analysis Software version 2.0. Results By evaluating 85 studies (10 in Asia, 56 in Europe, 2 in Africa and 17 studies in America) with a total sample size of 6628506 individuals, the prevalence of Dupuytren disease in the world is found as 8.2% (95% CI 5.7–11.7%). The highest prevalence rate is reported in Africa with 17.2% (95% CI 13–22.3%). According to the subgroup analysis, in terms of underlying diseases, the highest prevalence was obtained in patients with type 1 diabetes with 34.1% (95% CI 25–44.6%). The results of meta-regression revealed a decreasing trend in the prevalence of Dupuytren disease by increasing the sample size and the research year (P < 0.05). Conclusion The results of this study show that the prevalence of Dupuytren disease is particularly higher in alcoholic patients with diabetes. Therefore, the officials of the World Health Organization should design measures for the prevention and treatment of this disease.

show abstract

Section: Discussionmentioning

confidence: 61%

“…In a meta-analysis conducted by Lanting et al [ 75 ], the prevalence of Dupuytren in the Western countries was reported as 6–6.31% [ 75 ]. Also, Carloni et al [ 76 ], using a meta-analysis work, reported this rate as 1–5.9% [ 76 ]. Our study findings are almost in line with these research works.…”

Section: Discussionmentioning

confidence: 99%

The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…5,6,13,16 Os nódulos dorsais de Garrord foram mais frequentes no indicador, assim como descrito anteriormente. 17 Esses nódulos já foram associados com um risco aumentado da diátese da doença de Dupuytren. 18 O consumo de bebidas alcoólicas e o tabagismo já foram anteriormente associados com a doença de Dupuytren.…”

Section: Discussionunclassified

Epidemiologia da doença de Dupuytren e de pacientes submetidos a fasciectomia seletiva

Alencar

Perini

Monteiro

et al. 2021

Rev Bras Ortop (Sao Paulo)

View full text Add to dashboard Cite

Resumo Objetivo Descrever o perfil epidemiológico e clínico dos pacientes com doença de Dupuytren tratados por fasciectomia seletiva e os fatores associados com a gravidade da doença. Metodologia Estudo observacional descritivo retrospectivo envolvendo 247 pacientes com doença de Dupuytren, no período de 2013 a 2019. Foi realizada regressão logística multivariada para análise dos dados. Resultados A maioria dos pacientes era do sexo masculino (83,8%), autodeclarados brancos (65,2%), etilistas (59,6%), e 49% eram tabagistas. A média de idade foi de 66 ± 9 anos, sendo que 77,2% apresentaram os sintomas da doença após os 51 anos. Aproximadamente 51,9, 29,6, e 17,3%, respectivamente, apresentaram hipertensão arterial, diabetes mellitus e dislipidemia. O acometimento bilateral das mãos foi observado em 73,3% dos pacientes. A taxa de complicações intra- e pós-fasciectomia seletiva foi de 0,6 e 24,3%, respectivamente, sendo que 5,2% dos pacientes necessitaram de reintervenção após 1 ano de acompanhamento. Após análise multivariada, o sexo masculino foi associado com acometimento bilateral das mãos (odds ratio [OR] = 2,10; intervalo de confiança [IC] 95%: 1,03–4,31) e com maior número de raios acometidos (OR = 3,41; IC 95%: 1,66–7,03). A dislipidemia foi associada com a reintervenção (OR = 5,7; CI 95%: 1,03–31,4) e a bilateralidade com maior número de complicações (35,7% versus 19,7%). Conclusão Foi observada uma baixa taxa de reintervenção e complicações operatórias nos pacientes com doença de Dupuytren tratados por fasciectomia seletiva. O sexo masculino foi associado com o quadro grave da doença (bilateralidade e mais de dois raios acometidos), e a dislipidemia com a reintervenção.

show abstract

“…Dupuytren’s disease is a progressive fibromatosis of the palm and flexor side of the hand with similar, but more rare manifestations located on the dorsal PIP joints as knuckle pads (aka Garrod’s nodules) [ 1 ] [ 2 ], at the foot sole as Ledderhose’s disease [ 3 ], or at the dorsum of the penis in Peyronie’s disease. As is customary, Dupuytren starts with nodular manifestation in the palm of the hand and might progress to a pretendinous cord with consecutive finger joint contracture.…”

Section: Introductionmentioning

confidence: 99%

Focused electromagnetic high-energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren’s disease—a randomized controlled trial (DupuyShock)

et al. 2021

View full text Add to dashboard Cite

Dupuytren’s disease is a progressive fibroproliferative disorder of the hand. In the nodular stage of Dupuytren’s disease, pain might limit daily hand activities and progress to finger contractures. Focused electromagnetic high-energetic extracorporeal shockwave therapy (ESWT) may reduce pain in Dupuytren’s nodules (Tubiana N). In this prospective, randomized, blinded, placebo-controlled single center trial, we enrolled 52 patients (mean age, 58.2 ± 9.2) with painful nodular Dupuytren disease Tubiana N. Randomization was done to either (group A) 3 treatments with focused electromagnetic high-energetic ESWT (2000 shots, 3 Hz, 0.35 mmJ/mm2/hand, Storz Duolith SD1, n = 27) or (group B) placebo ESWT (2000 shots, 3 Hz, 0.01 mJ/mm2/hand, n = 25) in a weekly interval. Primary outcome was the level of pain on a visual analogue scale (VAS 0–10) at 3/6/12/18 months, secondary outcomes were patient-related outcome measures (DASH score, MHQ score, URAM scale), grip strength, patient’s satisfaction, and Dupuytren’s disease progression over 18 months follow-up. Focused ESWT significantly improved outcomes. Pain was reduced from 3.6 ± 1.8 to 1.9 ± 1.2 at three, to 1.4 ± 0.7 at six, to 1.7 ± 1.6 after 12 months and 1.9 ± 0.8 after 18 months in the intervention group (47% reduction, p < 0.05). In the placebo group, pain on VAS increased from 2.2 ± 1.4 to 3.4 ± 1.7 at three, to 3.4 ± 1.8 at six, to 3.4 ± 1.4 at 12 and 3.1 ± 1.1 at 18 months (35% increase, p < 0.05). Quality-of-life score tended to improve in the intervention group (MHQ, 77 ± 19 to 83 ± 12; DASH, 12 ± 18 to 10 ± 9) while it deteriorated in the placebo group as Dupuytren’s disease was progressing (MHQ, 79 ± 15 to 73 ± 17; DASH, 6 ± 10 to 14 ± 13). The strength of the affected hand and fingers did not change significantly in either of the groups. Patients’ satisfaction was higher in the intervention group for symptom improvement (56% vs. 12%) and reduction of disease progression (59% vs. 24%). Any Dupuytren-related intervention was performed in 26% in the intervention group and in 36% in the placebo group within 18 months of follow-up (n.s.). Focused electromagnetic high-energetic ESWT can significantly reduce pain in painful nodules in Dupuytren’s disease in an 18-month perspective. (ClinicalTrials.gov Identifier: NCT01184586).

show abstract

Dorsal Dupuytren’s disease: a systematic review of published cases and treatment options

Cited by 8 publications

References 38 publications

The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis

The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis

Epidemiologia da doença de Dupuytren e de pacientes submetidos a fasciectomia seletiva

Focused electromagnetic high-energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren’s disease—a randomized controlled trial (DupuyShock)

Contact Info

Product

Resources

About